DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: December 22, 2010

Department of Defense Prostate Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2011 (FY11)

The Department of Defense Prostate Cancer Research Program (PCRP) is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

Congressional funds for the FY11 PCRP have not yet been appropriated. However, the PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. The PCRP anticipates offering the following award mechanisms for FY11 pending the availability of congressional funds. This pre-announcement should not be construed as an obligation by the government.

IMPORTANT: The FY11 PCRP will use two Overarching Challenges and six Focus Areas to direct/frame applications for funding:
  • Overarching Challenges: Development of effective treatments for advanced prostate cancer, Distinguish aggressive from indolent disease
  • Focus Areas: Biomarkers, Genetics, Imaging, Survivorship, Therapy, Tumor Biology and Immunology
RESEARCH AWARDS
Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Trial Award Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Preproposal is required; application submission is by invitation only
  • Supports rapid execution of early phase clinical trials that have the potential for significant impact on prostate cancer
  • Studies may include evaluation of novel drug , biologic, device, surgical procedure, rehabilitative modality, behavioral or other intervention
  • Clinical trials are expected to be initiated upon receipt of award
  • Studies requiring funding in excess of the DOD award must provide evidence of the availability of such funding
  • If applicable, IND or IDE approval must be received prior to applying for this award
  • Preliminary data and clinical protocol are required
  • Maximum funding of $375K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Exploration-Hypothesis Development Award Investigators at all academic levels (or equivalent)
  • Supports highly innovative, untested, potentially groundbreaking concepts in prostate cancer
  • Emphasis is on innovation; potential impact may be unknown
  • Studies involving human subjects are permitted provided they are exempt from or qualify for expedited IRB review
  • Preliminary data are not allowed
  • Maximum funding of $75K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 12 months
Health Disparity Research Award Independent investigators at or above the level of Assistant Professor (or equivalent); or

New Investigator Option: PIs must meet the following criteria by the application submission deadline:
  • Must have the freedom to pursue individual aims without formal mentorship, AND
  • Have not previously received a PCRP New Investigator Award, AND
  • Either have completed at least 3 years of postdoctoral training OR are within 5 years of having received first independent faculty position (or equivalent)
  • Supports high-impact approaches to prostate cancer health disparity research that represent new ideas and, if successful, will significantly accelerate the elimination of death and suffering from prostate cancer
  • Member(s) of the research team should have a connection to, or effectiveness in working with, a disproportionately affected population or community
  • New Investigator Option supports applicants early in their faculty appointments or in the process of developing
  • Qualified Collaborator Option (QCO) qualifies studies for higher level of funding
  • Preliminary data are encouraged but not required
  • Clinical trials are not allowed
  • Maximum funding of $450K (or $600K for QCO) for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Idea Development Award Independent investigators at or above the level of Assistant Professor (or equivalent); or

New Investigator Option: PIs must meet the following criteria by the application submission deadline:
  • Must have the freedom to pursue individual aims without formal mentorship, AND
  • Have not previously received a PCRP New Investigator Award, AND
  • Either have completed at least 3 years of postdoctoral training OR are within 5 years of having received first independent faculty position (or equivalent)
  • Preproposal is required; application submission is by invitation only
  • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and, if successful, will significantly accelerate the elimination of death and suffering from prostate cancer
  • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers
  • Preliminary data are encouraged but not required
  • Clinical trials are not allowed
Established PIs (revised!):
  • Maximum funding of $375K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
New Investigator Option (revised!):
  • Maximum funding of $225K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Impact Award Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Preproposal is required; application submission is by invitation only
  • Supports high-impact studies towards reducing or eliminating the problem of overtreatment of primary prostate cancer
  • Areas of special interest include but are not limited to active surveillance, biomarkers, improved staging, local staging, and optimal measures for follow-up and biopsy
  • Multidisciplinary teams inclusive of strong clinical expertise are a key feature
  • Preliminary data to support feasibility are required
  • Allows clinical trials
  • Maximum funding of $750K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 4 years
Laboratory-Clinical Transition Award Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Preproposal is required; application submission is by invitation only
  • Supports goal- and product-driven preclinical studies of promising lead agents to IND and/or cGMP production that may revolutionize prostate cancer clinical care
  • PIs are expected to have identified and have access to either one lead agent or a limited number of lead agents and a validated target before applying
  • Preliminary data are required to demonstrate target availability and relevance to human prostate cancer and lead agent(s) mechanism of action and potential efficacy
  • Clinical trials are not allowed
  • Maximum funding of $750K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Population-Based Research Award Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Supports high-impact approaches to prostate cancer research from the perspective of population-based studies that will, if successful, significantly accelerate the elimination of death and suffering from prostate cancer
  • Population-based studies may include retrospective, prospective, case-control, cohort or other population-based study designs provided that the study population is of sufficient size to provide appropriate statistical power
  • Topics may include but are not limited to epidemiology, molecular genetics, genomics, risk prediction, disease aggressiveness, predictors of therapeutic response and progression, and health disparity
  • Requires a robust statistical plan and strong biostatistical expertise on the study team
  • Clinical trials are not allowed
  • Maximum funding of $600K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 4 years
Synergistic Idea Development Award Two or three independent investigators at or above the level of Assistant Professor (or equivalent)
  • Preproposal is required; application submission is by invitation only
  • Supports new or existing partnerships between two or three independent investigators to address a central innovative question in prostate cancer that may include high risk, provided there is a potential for significant impact
  • Preliminary data are encouraged but not required
  • Clinical trials are not allowed
  • Maximum combined funding of $750K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award Independent investigators at or above the level of Assistant Professor (or equivalent) with a proven record in prostate cancer research and training
  • Supports new or existing summer prostate cancer training programs for undergraduate HBCU students at host institutions
  • Must enroll a minimum of four undergraduate HBCU trainees per year
  • Host institution must have a record of achievement in prostate cancer research and training
  • Maximum funding of $185K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 3 years
Health Disparity Training Award Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Must be enrolled full-time in an accredited doctoral program and must have completed all predissertation requirements by October 1, 2011
Postdoctoral Ph.D. and M.D. PIs:
  • Must have successfully defended a doctoral thesis or possess and M.D. by October 1, 2011; and
  • Have 3 years or less of postdoctoral fellowship experience by October 1, 2011; and
  • Be able to devote at least 40% effort
  • Supports training in prostate cancer health disparity research for individuals in the early stages of their careers
  • PIs must have a designated mentor who is an experienced prostate cancer health disparity researcher
  • PI or mentor must demonstrate a connection to, or effectiveness in working with, the disproportionately affected population or community
Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Maximum funding of $92.5K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 3 years
Postdoctoral Ph.D. and M.D. PIs:
  • Maximum of $115K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years
Physician Research Training Award At the time of proposal submission, the PI must be either:
  • A physician with clinical duties and/or responsibilities in the last year of an accredited medical residency or medical fellowship program; or
  • A physician within 3 years of first independent faculty appointment
  • Supports training of physicians with clinical duties for careers in prostate cancer research
  • Individualized training program and mentorship should prepare the PI for an independent career as a leader in prostate cancer research
  • Institutions must provide at least 40% protection of PI's time for research
  • Maximum funding of $130K per year for direct costs (plus 8% indirect costs)
  • Period of performance is 3 years minimum to 5 years maximum
Postdoctoral Fellowship Award
  • Must have successfully defended a doctoral thesis or possess an M.D. (or equivalent) by October 1, 2011; and
  • Have 3 years or less of postdoctoral fellowship experience by October 1, 2011; and
  • Be able to devote at least 40% effort
  • Supports prostate cancer research training for talented individuals in the early stages of their careers
  • Individualized training program and mentorship should prepare the PI for an independent career as a leader in prostate cancer research
  • Maximum of $115K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years

The government reserves the right to make changes to the award mechanisms offered and the mechanism elements if necessary. All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required for all award mechanisms and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to application submission. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact: